MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups

(2015) Michael Weller et al.   ACTA NEUROPATHOLOGICA

Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

(2015) Chih-Yi Hsu et al.   JOURNAL OF NEURO-ONCOLOGY

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

(2014) Anna Sophie Berghoff et al.   NEURO-ONCOLOGY

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

Pyrosequencing of IDH1 and IDH2 Mutations in Brain Tumors and Non-neoplastic Conditions

(2012) Matthew D. Cykowski et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide

(2012) Moritz Stuplich et al.   JOURNAL OF CLINICAL ONCOLOGY

EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

(2012) E. Franceschi et al.   NEURO-ONCOLOGY

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice

(2012) M. Weller et al.   NEURO-ONCOLOGY

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts

(2011) Deborah S. Malley et al.   ACTA NEUROPATHOLOGICA

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma

(2011) Qi SongTao et al.   CANCER SCIENCE

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas

(2011) Jörg Felsberg et al.   INTERNATIONAL JOURNAL OF CANCER

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

(2010) Markus Christmann et al.   INTERNATIONAL JOURNAL OF CANCER

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

(2009) Sibille Everhard et al.   NEURO-ONCOLOGY

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model

(2008) Gaspar J. Kitange et al.   JOURNAL OF NEURO-ONCOLOGY